Tenon Medical, Inc. (TNON) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tenon Medical, Inc. on May 17, 2023. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Los Gatos, California. Its common stock trades on The Nasdaq Capital Market under the symbol "TNON".
Key Financial Metrics
The filing references the Company's stockholders' equity as reported in its Form 10-Q for the quarter ended March 31, 2023.
- Stockholders' Equity: $2,474,000
- Nasdaq Minimum Requirement: $2,500,000
- Revenue, Profit, Cash Flow, Debt: The filing text does not provide specific values for these metrics.
Material Changes and Events
On May 17, 2023, the Company received a written notice from The Nasdaq Stock Market LLC stating it is no longer in compliance with the minimum stockholders' equity requirement (Listing Rule 5550(b)(1)). The reported equity of $2,474,000 falls below the required $2,500,000 threshold. The Company also does not currently meet alternative compliance standards regarding market value of listed securities or net income from continuing operations.
Outlook, Risks, and Management Commentary
The Company has 45 calendar days to submit a plan or regain compliance, with a specific deadline of July 3, 2023, to submit a plan. If a plan is accepted, Nasdaq may grant an extension of up to 180 calendar days (until November 13, 2023) to regain compliance. Management is evaluating various courses of action and intends to submit a plan timely. However, there is no assurance that the plan will be accepted or that compliance will be achieved. Failure to regain compliance could result in delisting, though the Company retains the right to request a hearing before an independent Hearings Panel for an additional extension. The notice has no immediate effect on the listing, trading, or operations of the Company.
Key Facts for Investor Verification
- Verify the Company's stockholders' equity balance as of the most recent reporting period to confirm the deficit against the $2.5 million Nasdaq requirement.
- Monitor the Company's submission of a compliance plan to Nasdaq by the July 3, 2023 deadline.
- Review the Company's Form 10-Q for the quarter ended March 31, 2023, for detailed financial statements and cash flow data not included in this 8-K.
- Track any subsequent announcements regarding the acceptance of the compliance plan or potential delisting proceedings.